Prosecution Insights
Prosecution Insights
16 pending office actions • 10 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (25%) |
| §102 only | 1 (6%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 6 (38%) |
| No statute on record | 2 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 69.9% | +31.3% |
| BRAUN, MADELINE E | 1 | 67.6% | +26.4% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.1% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.6% | +31.9% |
| MEAH, MOHAMMAD Y | 1 | 70.9% | +42.6% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 33.3% | +0.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.1% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.5% |
| NGUYEN, QUANG | 1 | 38.1% | +53.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | CRAIGO, BAHAR ALAWI | 10d overdue |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 19d |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | CRAIGO, BAHAR ALAWI | 10d overdue |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 9d overdue |
| 18276954 | Recombinant Human Acid Alpha-Glucosidase and Uses Thereof | BERKE-SCHLESSEL, DAVID W | 15d |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 19d |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | — |
| 18473622 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | NOAKES, SUZANNE MARIE | — |
| Art Unit | Apps |
|---|---|
| 1656 | 3 |
| 1652 | 2 |
| 1622 | 2 |
| 1653 | 2 |
| 1624 | 1 |
| 1651 | 1 |
| 1699 | 1 |
| 1631 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — | §102§103 | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | 1624 | §102DPOther | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18473622 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | NOAKES, SUZANNE MARIE | 1656 | §112Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18276954 | Recombinant Human Acid Alpha-Glucosidase and Uses Thereof | BERKE-SCHLESSEL, DAVID W | 1651 | §102Other | Final Rejection | 15d | Pending | Aug 11, 2023 |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | 9d overdue | Pending | Feb 17, 2023 |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§112 | Non-Final OA | — | Pending | Feb 07, 2023 |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2022 |
| 17838820 | Use Of Migalastat For Treating Fabry Disease In Pregnant Patients | CRAIGO, BAHAR ALAWI | 1699 | §102§103 | Final Rejection | 10d overdue | Pending | Jun 13, 2022 |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 1656 | §103§112 | Non-Final OA | 19d | Pending | Jun 13, 2022 |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 1631 | §102§103 | Non-Final OA | 27d | Pending | Apr 29, 2022 |
| 17640456 | Method For Capturing And Purification Of Biologics | AFREMOVA, VERA | 1653 | §103 | Non-Final OA | 12d | Pending | Mar 04, 2022 |
| 17665969 | Methods for Treatment of Fabry Disease | JAVANMARD, SAHAR | 1622 | Other | Final Rejection | 70d overdue | Pending | Feb 07, 2022 |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | Jul 22, 2021 |
| 17079859 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | TSAY, MARSHA M | 1656 | Other | Non-Final OA | — | Pending | Oct 26, 2020 |
| 16967824 | Treatment Of Patients With Classic Fabry Disease | CHONG, YONG SOO | 1623 | §103Other | Final Rejection | 32d overdue | Pending | Aug 06, 2020 |
| 14398210 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Oct 31, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial